Market News Archives

Jazz Pharmaceuticals’ Chimerix Acquisition Marks Significant Milestone In Precision Neuro-Oncology – ( $JAZZ $CMRX $LTRN )

by John F. Heerdink, Jr. March 6, 2025 499Views 0Likes

Jazz Pharmaceuticals Chimerix Acquisition is attracting attention as recent market developments continue to evolve. Jazz Pharmaceuticals Chimerix Acquisition Jazz Pharmaceuticals' (NASDAQ: JAZZ) $935 million acquisition of Chimerix (NASDAQ: CMRX) marks a significant milestone in precision neuro-oncology, highlighting the growing potential of targeted…

Indaptus Emerging With Potential Keytruda Partner or Competitor – ( $MRK $INDP $IBB )

by John F. Heerdink, Jr. February 10, 2025 529Views 0Likes

Indaptus Therapeutics (NASDAQ: INDP) , a clinical-stage biotechnology company pioneering innovative cancer and viral infection treatments, has received approval from Health Canada to expand its clinical trial of Decoy20, a promising cancer treatment, into Canada, broadening patient recruitment for its ongoing U.S.-based…

Can PD1xVGEF Bifunctional Antibodies displace Keytruda and Opdivo in Immuno-Oncology? – $MRK $BMY $SMMT $BNTX $GLYC $NAYA

by Vista Partners LLC January 9, 2025 722Views 0Likes

Eupraxia Pharma’s DiffuSphere Technology Has Shown Promising Results In Pain, Infectious Diseases, Eye Diseases And Cancers

by Vista Partners LLC January 1, 2025 488Views 0Likes

Eupraxia Pharma's (NASDAQ: EPRX) DiffuSphere technology has shown promising results in targeted drug delivery for cancer treatment. The company recently announced that its novel technology demonstrated successful targeted delivery of a chemotherapeutic agent to tumors in animal models. Key Highlights Targeted Drug…

Market News

Jazz Pharmaceuticals’ Chimerix Acquisition Marks Significant Milestone In Precision Neuro-Oncology – ( $JAZZ $CMRX $LTRN )

Indaptus Emerging With Potential Keytruda Partner or Competitor – ( $MRK $INDP $IBB )

Can PD1xVGEF Bifunctional Antibodies displace Keytruda and Opdivo in Immuno-Oncology? – $MRK $BMY $SMMT $BNTX $GLYC $NAYA

Eupraxia Pharma’s DiffuSphere Technology Has Shown Promising Results In Pain, Infectious Diseases, Eye Diseases And Cancers

Your Guide To Staying Informed In The Markets